Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CalciMedica, Inc. (GRAY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/11/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Updated Business Description",
"Audited recasted financial statements of Private CalciMedica as of and for the years ended December 31, 2022 and 2021"
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates"
06/28/2023 ARS Form ARS - Annual Report to Security Holders:
06/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CalciMedica Announces Relisting on Nasdaq June 12, 2023 11:30 AM EDT LA JOLLA, Calif., June 12, 2023 - CalciMedica Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced that The Nasdaq Stock Market LLC has approved CalciMedica's application for the relisting of the Company's common stock on the Nasdaq Capital Market. The Company's common stock is expected to commence trading on the Nasdaq Capital Market at the opening of trading on Wednesday, June 14, 2023, under the ticker symbol “CALC”. CalciMedica's common stock will continue to trade on the OTCQB until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol “CALC”. “We are pleased that we are r..."
05/23/2023 SC 13D/A Flynn James E reports a 4.9% stake in CalciMedica, Inc.
05/15/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates LA JOLLA, CA, May 15, 2023 - CalciMedica Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended March 31, 2023. “We ended our first quarter as a public company in a strong position, with a cash runway that will last into the second half of 2024,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. “We are pleased to have entered the second quarter of 2023 with forward momentum, continuing the work towards our near-term clinical milestones with Auxora in acute pancreatitis and asparaginase-associated pancreatitis for critically ..."
05/12/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Quarterly results
04/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/04/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/04/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Audited Financial Statements of CalciMedica, Inc. for the years ended December 31, 2022 and 2021",
"Unaudited Pro Forma Combined Financial Statements"
04/04/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/04/2023 D Form D - Notice of Exempt Offering of Securities:
03/28/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/27/2023 SC 13D/A Flynn James E reports a 24.5% stake in CalciMedica, Inc.
03/24/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 5.4% stake in CalciMedica, Inc.
03/22/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GRAYBUG VISION, INC., a Delaware corporation; CAMARO MERGER SUB, INC., a Delaware corporation; and CALCIMEDICA, INC.,",
"Amended and Restated Certificate of Incorporation of Graybug Vision, Inc",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Graybug Vision, Inc",
"Certificate of Merger",
"Form of Registration Rights Agreement, by and among CalciMedica, Inc. and the several purchasers signatory thereto",
"Form of Warrant to Purchase Shares of Series D Convertible Preferred Stock of CalciMedica, Inc",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to Eric Roberts",
"Warrant to Purchase Common Stock, issued by CalciMedica, Inc. to Fred Middleton"
03/15/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
02/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 5.7% stake in Graybug Vision, INC.
02/06/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
01/31/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
01/20/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
12/28/2022 8-K Quarterly results
12/14/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
12/01/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy